Novartis to Buy Big Stake in Alnylam as Part Of RNAi Alliance; Deal Could Be Worth $700M

The collaboration, in which Novartis will gain a 19.9-percent stake in Alnylam, will enable the RNAi company to increase its headcount by more than one-third and continue to operate through 2010. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.